Identiv, Inc. (INVE)

CTI BioPharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	25.24	26.63	43.45	112.92	103.77	86.92
Revenue Growth (YoY)	-38.76%	-38.71%	-61.52%	8.81%	19.38%	3.78%
Cost of Revenue	25.25	26.29	37.44	71.97	66.7	53.24
Gross Profit	-0.01	0.34	6.01	40.94	37.07	33.68
Selling, General & Admin	23.78	23.87	14.96	31.16	28.92	25.89
Research & Development	3.78	3.89	4.4	9.92	8.67	9.78
Operating Expenses	27.56	27.76	19.36	41.08	37.6	35.67
Operating Income	-27.57	-27.42	-13.35	-0.13	-0.53	-1.99
Interest Expense	-	-	-0.43	-0.14	-0.48	-1.46
Interest & Investment Income	2.65	1.35	-	-	-	-
Currency Exchange Gain (Loss)	0.48	0.79	-0.01	0.16	-0.08	-0.12
EBT Excluding Unusual Items	-24.43	-25.28	-13.79	-0.12	-1.09	-3.58
Merger & Restructuring Charges	-0.8	-0.54	-0.16	-0.2	-0.82	-1.72
Gain (Loss) on Sale of Investments	-	-	0.13	0.03	0.61	-
Other Unusual Items	-	-	-	-	2.95	0.26
Pretax Income	-25.23	-25.82	-13.81	-0.29	1.65	-5.03
Income Tax Expense	0.09	0.09	0.07	0.1	0.03	0.07
Earnings From Continuing Operations	-25.32	-25.91	-13.88	-0.39	1.62	-5.11
Earnings From Discontinued Operations	99.91	100.73	8.39	-	-	-
Net Income to Company	74.59	74.82	-5.49	-0.39	1.62	-5.11
Net Income	74.59	74.82	-5.49	-0.39	1.62	-5.11
Preferred Dividends & Other Adjustments	0.84	0.88	1.27	1.21	1.15	1.09
Net Income to Common	73.75	73.94	-6.76	-1.6	0.47	-6.2
Shares Outstanding (Basic)	24	24	23	23	21	18
Shares Outstanding (Diluted)	24	24	23	23	22	18
Shares Change (YoY)	1.84%	2.22%	1.80%	1.76%	23.86%	5.85%
EPS (Basic)	3.12	3.14	-0.29	-0.07	0.02	-0.34
EPS (Diluted)	3.12	3.14	-0.29	-0.07	0.02	-0.34
Free Cash Flow	-18.97	-16.93	-3.13	-11.71	-0.86	-3.33
Free Cash Flow Per Share	-0.80	-0.72	-0.14	-0.52	-0.04	-0.18
Gross Margin	-0.04%	1.28%	13.83%	36.26%	35.72%	38.75%
Operating Margin	-109.22%	-102.98%	-30.72%	-0.12%	-0.51%	-2.29%
Profit Margin	292.20%	277.67%	-15.55%	-1.42%	0.46%	-7.13%
Free Cash Flow Margin	-75.18%	-63.57%	-7.20%	-10.37%	-0.83%	-3.83%
EBITDA	-26.18	-25.44	-12.04	2.1	1.39	1.24
EBITDA Margin	-103.72%	-95.55%	-27.70%	1.86%	1.34%	1.43%
D&A For EBITDA	1.39	1.98	1.31	2.23	1.92	3.24
EBIT	-27.57	-27.42	-13.35	-0.13	-0.53	-1.99
EBIT Margin	-109.22%	-102.98%	-30.72%	-0.12%	-0.51%	-2.29%
Effective Tax Rate	-	-	-	-	1.70%	-

Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q